Intraventricular Hemorrhage
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Heidelberg PharmaGermany - Ladenburg
1 programExternal drainage of intraventricular hemorrhageN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
GenentechAlteplase
Heidelberg PharmaExternal drainage of intraventricular hemorrhage
Genomicscollection of CSF and blood
Clinical Trials (3)
Total enrollment: 855 patients across 3 trials
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
Start: Jul 2009Est. completion: Jan 2016500 patients
Phase 3Completed
Lumbar Drainage of Intraventricular Hemorrhage
Start: Jan 2025Est. completion: Jul 2029354 patients
N/ARecruiting
Micro Ribonucleic Acid (miRNA) Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH)
Start: Mar 2015Est. completion: Dec 20161 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 855 patients
3 companies competing in this space